Show notes
In this podcast, we spoke with Troy Ostreng, Senior Product Manager and David Burdge, Director of Cell and Gene Therapy at CPC about the development of the MicroCNX® aseptic micro-connectors and how they’re helping biopharma teams streamline closed-system operations for cell and gene therapies. What unfolded was a detailed and forward-looking conversation that touched on CPC’s 47-year legacy, the technical demands of advanced therapies, and the company’s plans to drive the future of automation and sterility in manufacturing.
A Legacy That Positioned CPC for Today’s Advanced Therapy Boom
When asked how CPC’s long history in biologics and hospital environments prepared the company for today’s cell and gene therapy landscape, David took us back to CPC’s roots. “CPC was founded in 1978, so that’s 47 years of innovation within connection technologies,” he said. “The first biologic was released in 1982, synthetic insulin, and we were there supporting the industry with open-format connectors on single-use bags.”
From the early development of biologics through the shift to single-use and the rise of stainless-steel/single-use hybrid systems, CPC continuously evolved its connection technologies. They launched steam-through connectors as bioprocessing grew more complex, released their first aseptic connector in 2009, and introduced their first connector specifically targeted for the cell and gene therapy market in 2017.
David explained how that history matters today: “Biologics has about a 35-year head start on advanced therapies. So the question becomes, what lessons can we transfer from biologics to cell and gene therapy as that industry grows at three to four times the rate biologics did in its first decade?”
That perspective, combining biological manufacturing experience with the needs of new therapy modalities, forms the foundation for CPC’s MicroCNX platform.
MicroCNX: The First Aseptic Connector Built for Small-Format Tubing
As cell and gene therapy developers began scaling up manufacturing, they quickly discovered a problem: the connectors used for biologics were not designed for small-volume, patient-specific therapies. Troy described it plainly: “Several years ago, we started hearing rumblings that current connectors weren’t meeting what cell and gene therapy required.”
CPC responded with a deep Voice of Customer (VOC) initiative, interviewing process engineers, operators, manufacturing leaders, and platform developers. Over and over, the same needs emerged.
Operators wanted something simple. “Ease of use was the number one requirement,” Troy said. “Operators needed a product that was easy to use so they could make sterile connections in a short amount of time.”
Processes demanded robustness. “Customers needed a connection they could trust—no contamination, no failures, no weak spots in the connection process,” he added.
Small-volume precise applications required connectors actually designed for them. With autologous therapies, he noted, “We aren’t talking about 1,000 liters; we’re talking about 250 milliliters. And if there’s a mishap, that could mean the difference between life and death for a patient.”
All of this laid the groundwork for MicroCNX, which became the first aseptic connector engineered for small-format tubing.
The “Pinch-Click-Pull” Process: Sterility Meets Speed
One of the standout features of MicroCNX is its elegantly simple pinch-click-pull operation. Troy explained how simplicity came directly from user feedback. “As operators walked us through their pain points, what they needed was clear: a connector they could learn immediately. So MicroCNX has a three-step process—pinch, click, pull. You can literally do it as fast as I say it.” He continued,“Once someone does it one time, they’re basically an expert. That ease of use dramatically reduces operator error.” For an industry where operator variability remains one of the biggest sources of risk and batch loss, eliminating complexity is critical.
Cryogenic Challenges Call for Cryo-Rated Solutions
As the conversation shifted to cryopreservation, a critical component of cell therapy manufacturing,Troy introduced the MicroCNX® ULT and MicroCNX® Nano variants. “These were really developed because therapies were being frozen to –150°C, even –190°C. You need a connector that can be frozen to those temperatures, thawed, and still be as robust as it was before.”
The ULT and Nano were engineered with:
Low-profile geometries to fit inside freezing cassettes
Specialized materials to withstand thermal stress
Chemical compatibility with DMSO and other cryoprotectants
Enhanced durability to survive impacts while frozen
Troy emphasized how critical it was to get the materials right: “We searched extensively for a material that could handle those harsh chemicals and temperatures. What we landed on was PPSU—polyphenylsulfone. It’s chemically sound, and it’s incredibly impact-resistant at very low temperatures.” CPC built these connectors because customers repeatedly told them: existing solutions were cracking, leaking, or becoming brittle. MicroCNX was engineered to overcome all of that.
True Closed Systems vs. Functionally Closed Systems: Why the Difference Matters
A substantial part of the conversation focused on the differences between closed, functionally closed, and open systems—distinctions that are often overlooked but critically important.
Troy broke down the differences clearly: “An open system is exposed at some point. A functionally closed system is inherently open but gets closed temporarily to let fluid transfer. In comparison, a closed system is never open at any point.”
Examples of functionally closed systems include:
Biosafety cabinets (BSCs)
Luer-based connections
Closed system transfer devices
These approaches require:
Sanitization
Careful environmental controls
Operator expertise
And, as Troy noted, “a mishap in one of these can mean losing a very valuable therapy.”
CPC’s sterile connectors—including MicroCNX minimize these risks: “Our connectors allow the system to remain closed 100% of the time. That greatly reduces contamination risk.”
This distinction isn’t merely academic—it has direct regulatory implications as well. David added,“In Annex 1, they refer to intrinsically sterile connection devices—like sterile connectors and tube welders—that allow operations normally requiring Grade A or B to occur in a Grade C or D environment.” That ability to operate safely in lower-grade spaces is increasingly critical as the industry tries to overcome facility and labor bottlenecks.
Why Teams Are Moving Away from Tube Welding
Tube welding has been part of bioprocessing for decades, but David explained why its era may be ending for CGT. “Tube welding was born out of the blood banking industry when no other solution existed. But sterile connectors don’t require capital investment. They’re faster. They eliminate issues like tubing alignment or pinhole leaks. They’re simply more reliable.” As biologics manufacturers have already done, CGT teams are now transitioning toward connectors like MicroCNX® that provide sterile, consistent, low-burden operations.
The MicroCNX® Luer Variant: Supporting Transitional Workflows
Not all workflows are ready to move away from luer-based devices. That’s where the MicroCNX Luer variant fits in.
Troy described how it works.“You connect a syringe or bag with a luer inside the BSC, but then because the MicroCNX® connector itself is sterile, you can take it outside the hood and make a sterile connection elsewhere.” This capability bridges legacy workflows and fully closed systems—critical during process development, technology transfer, or when working with specific devices.
Co-Development: The Heart of CPC’s Innovation Process
As the conversation returned to CPC’s broader philosophy, David highlighted how important customer collaboration is. “It’s all about the customer for CPC,” he said. “We start with Voice of Customer. Our business and applications managers are out in the field understanding real applications and guiding them to the right products.”
This feedback fuels CPC’s two major development tracks:
Catalog product development (platforms like MicroCNX)
Custom-engineered solutions for unique applications
David added: “We maintain a full new product introduction roadmap. Some products will be released broadly. Others will be developed specifically for one customer. But both are driven by real application requirements.” This process ensures CPC’s products evolve in lockstep with the needs of advanced therapy teams.
Looking Ahead: Designing Connectors for Robotics and Automation
Toward the end of the conversation, David turned to one of CPC’s biggest focus areas: the future of automation. “The ultimate customer in this industry is the patient,” he said. “And right now we face barriers—capacity, speed, accessibility, cost. Process automation can significantly reduce those barriers.”
Automation requires connectors designed not just for human hands but for robotics:
Predictable geometries
Features optimized for machine vision
Forces and actuation steps compatible with robotic grippers
Designs intended for automated loading and unloading
David summarized CPC’s future direction: “We’re taking a fresh look at our connectors, reimagining them as something designed for robotic manipulation. It’s a high priority for us.” Troy echoed the sentiment: “Our connectors are awesomely designed for humans. But automation is coming, and we’re focused on the features robots need.”
A Future Built on Innovation and Patient Impact
The interview closed with both guests reflecting on CPC’s mission.
“We’re incredibly passionate about innovation and meeting the needs of our customers through thoughtful product development,” Troy said.